IBA Strengthens its Dosimetry Portfolio with Acquisition of Modus Medical Devices Inc.
03 Mai 2022 - 7:00AM
IBA Strengthens its Dosimetry Portfolio with Acquisition of Modus
Medical Devices Inc.
Acquisition strengthens IBA’s Dosimetry
operations in North America and adds one of the most comprehensive
dosimetry “phantom” offerings on the market
Louvain-la-Neuve, Belgium, 3 May
2022 - IBA (Ion Beam Applications S.A., EURONEXT), the
leader in particle accelerator technology and the leader in
dosimetry quality assurance solutions, today announces it has
acquired Modus Medical Devices Inc. (Modus QA), a Canadian company
based in London, Ontario, specialized in phantoms for quality
assurance for radiation therapy.
Founded in 2000 and employing about 20 people,
Modus QA is at the forefront of quality assurance for complex
radiation therapy technologies, such as image-guided radiation
therapy (IGRT), surface guided radiation therapy (SGRT) and
respiratory gating that have led to significant advances in patient
treatment. It specializes in phantoms, a manufactured product made
to resemble human organ or tissue used to quantify the potential
effects of a radiation dose on a patient. The company has a solid
installed base, with over 6,500 phantoms used in more than 4,000
clinics and hospitals worldwide. Built on science, research,
development and collaboration with medical physicists, Modus QA is
fully committed to delivering the accuracy needed to provide the
best patient care.
Through this acquisition, IBA will benefit from
synergies both in R&D and in sales and enable it to diversify
its product catalogue. This should strengthen IBA’s competitive
position globally as well as its footprint in North America. Thanks
to the complementary products from Modus QA, IBA Dosimetry will be
able to market the most advanced range of phantoms for radiation
therapy quality assurance, strengthening its leading position in
this segment. IBA will leverage its large client base to channel
Modus QA’s products and, therefore, expand their reach to new
markets in Europe and Asia.
Together, IBA and Modus QA will expand their
product portfolio in medical imaging and in proton therapy and
further strengthen existing relationships with Original Equipment
Manufacturers (OEMs). In addition, within proton therapy, Modus
QA’s expertise will enable IBA to develop new dosimetry products,
in order to offer an end-to-end range of quality assurance products
to proton therapy centers.
Jean-Marc Bothy, President of IBA
Dosimetry, commented: “Modus QA are
renowned experts in the dosimetry space and this highly
complementary acquisition further enhances our world leading
dosimetry offering. We are very pleased to welcome the Modus QA
team’s expertise to the Dosimetry team, and are looking forward to
working together to deliver IBA Dosimetry’s mission to treat even
more patients safely.”
Olivier Legrain, Chief Executive Officer
of IBA, added: “We welcome all Modus
employees to the IBA family. This acquisition is not just important
for the Dosimetry business, but is reflective of our wider company
strategy to seek out value-enhancing business opportunities to
build out our state-of-the-art product offering across our target
markets.”
***Ends***
About IBAIBA (Ion Beam
Applications S.A.) is the world leader in particle accelerator
technology. The company is the leading supplier of equipment and
services in the field of proton therapy, considered to be the most
advanced form of radiation therapy available today. IBA is also a
leading player in the fields of industrial sterilization,
radiopharmaceuticals and dosimetry. The company, based in
Louvain-la-Neuve, Belgium, employs approximately 1,600 people
worldwide. IBA is a certified B Corporation (B Corp) meeting the
highest standards of verified social and environmental
performance.
IBA is listed on the pan-European stock exchange
EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found at:
www.iba-worldwide.com
About Modus Medical Devices
IncFor over 20 years, Modus QA has been at the forefront
of quality assurance in the field of advanced radiotherapy and
medical imaging. We have earned the trust of the world’s leading
medical physicists by creating phantoms and software that help them
fulfill their responsibilities with the utmost confidence. Founded
in science and committed to collaboration, as treatment and imaging
options continue to evolve, we continue to innovate – enabling
accuracy when it matters most.
CONTACTS
Soumya
ChandramouliChief Financial Officer+32 10
475 890Investorrelations@iba-group.com
Olivier LechienCorporate
Communication Director+32 10 475 890communication@iba-group.com
Consilium Strategic
CommunicationsAmber Fennell, Angela Gray, Lucy
Featherstone+44 (0) 20 3709 5700IBA@consilium-comms.com
- 220503-IBA-Modus-Acquisition-EN
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024